Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)

dc.contributor.authorAkarca, U.
dc.contributor.authorHatzis, G.
dc.contributor.authorKitis, G.
dc.contributor.authorShouval, D.
dc.contributor.authorLai, C.
dc.contributor.authorCheinquer, H.
dc.contributor.authorChang, T.
dc.contributor.authorZink, R.
dc.contributor.authorZhu, J.
dc.contributor.authorBrett-Smith, H.
dc.date.accessioned2019-10-27T19:17:13Z
dc.date.available2019-10-27T19:17:13Z
dc.date.issued2006
dc.departmentEge Üniversitesien_US
dc.identifier.endpage5en_US
dc.identifier.issn1478-3223
dc.identifier.startpage5en_US
dc.identifier.urihttps://hdl.handle.net/11454/38332
dc.identifier.volume26en_US
dc.identifier.wosWOS:000239938800011en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherBlackwell Publishingen_US
dc.relation.ispartofLiver Internationalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleEntecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)en_US
dc.typeConference Objecten_US

Dosyalar